Summa Therapeutics, LLC

Summa Therapeutics is a commercial-stage medical device company specializing in advanced catheter technologies for peripheral vascular interventions. The company develops multifunctional catheters designed to improve the efficiency, safety, and economics of below-the-knee (BTK) revascularization procedures for patients with peripheral arterial disease (PAD). Summa's flagship product, Finesse BTK Multicath™, is an FDA-cleared trimodal catheter that combines crossing, diagnostic angiography, and angioplasty balloon functions in a single device. This integrated approach reduces the need for multiple catheter exchanges during complex peripheral interventions, thereby decreasing procedure time, radiation exposure, and contrast agent use—particularly important for at-risk patients with diabetes or chronic kidney disease. The Finesse product line, including the newly cleared Gen 2 injectable angioplasty balloon variant, addresses a critical clinical need in limb-salvage interventions, streamlining workflows and improving patient outcomes while reducing operator strain.